Major milestones in 2024
A year of ground-breaking achievements
Celebrating 80 years of innovation and our focus on medical dermatology
Go back to Almirall at a glance
PORTFOLIO
01
Ebglyss® (lebrikizumab) present across 10 countries in Europe
2024
02
Ilumetri® (tildrakizumab) achieved a record-breaking milestone by surpassing €200 MM in sales
2024
03
Wynzora® (calcipotriene and betamethasone dipropionate) achieved treatment of more than 240,000 patients treated, delivering 25.9 MM euros in net sales, and growth of over 53% (+ 9 million €) compared to 2023¹
2024
04
Klisyri® (tirbanibulin) reaching more than 400,000 patients², achieving net sales of 24.5 MM euros
2024
05
License agreement with Novo Nordisk for an anti-LI-21 monoclonal antibody, aimed at developing a first-in-class agent in dermatology
february 2024
1 PsO PowerBI Dashboard (IQVIA Midas data).
2 AK PowerBI Dashboard (IQVIA Midas data).
06
Exclusive agreement with Eloxx pharmaceutical to license ZKN-013 for rare dermatological diseases
march 2024
07
FDA approval for expanded area of use of our actinic keratosis treatment (tirbanibulin) of the face or scalp, with larger package size.
june 2024
08
Completion of decentralized regulatory approval procedure for our onychomycosis treatment (efinaconazole) in Europe
october 2024
09
Ebglyss® (lebrikizumab), with a reach of over 3,500 patients and net sales of nearly 33 MM dollars and an exceeded growth of 70%
december 2024
10
Presented cutting-edge medical dermatology advances at American Academy of Dermatology (AAD), International Federation of Psoriatic Disease Associations (IFPA), and the Psoriasis from Gene to Clinic Congress
march, june & december 2024
COLLABORATION
01
Initiation of a collaboration with Microsoft to advance AI tools propelling treatment development for skin diseases
january 2024
02
Partnership with the Centre for Genomic Regulation (CRG) to identify biomarkers for novel atopic dermatitis treatments
february 2024
03
International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
may 2024
and presentation of emerging data on biologics at the European Academy of Dermatology and Venereology (EADV)
september 2024
04
Skin Academy (April 2024) and Immunoskin:
Almirall’s collaboration conferences for leading experts in dermatology to advance scientific knowledge and the treatment of
skin conditions
OCTOBER 2024
PURPOSE
01
Celebrating 80 years of innovation and the history of Almirall
2024
02
Launch of the third edition of the Almirall-initiated AK Global Day
to raise awareness of actinic keratosis
may 2024
03
Launch of Act4impact:
our updated sustainability strategy for 2030
june 2024
04
Launch of the campaign #TrueColorsUnfiltered to raise awareness of atopic dermatitis
September 2024
05
Launch of the campaign ''Me & My Inner Circle'' to shed light on psoriasis
october 2024
06
Launch of Almirall Innovation Hub “The Hive”:
a collaborative environment at our R&D centre featuring a partnership with three companies
december 2024
